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Abstract
Necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) are the most common acute surgical
emergencies associated with high morbidity and mortality in preterm infants. We aimed to compare the profiles of
immunoregulatory proteins and identify novel mediators in plasma of NEC and SIP infants. We also investigated the
expression of target genes in resected intestinal tissues and an enterocyte cell line. Using Cytokine Antibody Array assay, we
reported the first comparative profiles of immunoregulatory proteins in plasma of NEC and SIP infants, and showed that
dysregulated proteins belonged to functionally diversified categories, including pro- and anti-inflammation, angiogenesis,
cell growth, wound healing, anti-apoptosis, cell adhesion and extracellular matrix reorganization. Validation by ELISA
confirmed significantly higher concentrations of interleukin (IL)-6, angiopoietin (Ang)-2, soluble type II interleukin-1 receptor
(sIL-1RII), and soluble urokinase-type plasminogen activator receptor (suPAR) in NEC infants compared with gestational age-
matched control, and a lower level of an epidermal growth factor receptor, secreted form of receptor tyrosine-protein
kinase ErbB3 (sErbB3), compared with SIP infants. mRNA expressions of IL1-RII and uPAR were up-regulated in resected
bowel tissues from NEC infants, indicating that immunoregulation also occurred at the cellular level. In FHs-74 Int cells, Ang-
2, IL1-RII and uPAR mRNA expressions were significantly induced by the combined treatment with lipopolysaccharide (LPS)
and platelet activating factor (PAF). Our study provided plasmatic signatures of immunoregulatory proteins in NEC and SIP
infants, and demonstrated involvement of multiple functional pathways. The magnitude of changes in these proteins was
significantly more extensive in NEC infants, reflecting the different nature of injury and/or severity of inflammation. We
speculate that dysregulation of IL-6, Ang-2, IL-1RII and uPAR occurred at both systemic and cellular levels, and probably
mediated via LPS and endogeneous PAF signals. Such exaggerated immunologic responses may account for the high
morbidity and mortality in NEC compared with SIP patients.
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Introduction
Necrotizing enterocolitis (NEC) and spontaneous intestinal
perforation (SIP) are the most frequently encountered surgical
emergencies with devastating consequences in preterm infants.
Although both conditions may present with intestinal perforation,
most neonatologists consider them as two distinct clinical entities
with different clinical profile and natural history. Infants with SIP
tend to be lower birth weight and have earlier onset of illness
compared with NEC infants [1]. A proportion of cases is
associated with the use of drugs, such as indomethacin and
corticosteroids [2,3]. At the early stage of presentation, SIP infants
have marked clinical stability as well as lacking signs and
symptoms suggestive of a severe illness or peritonitis [1].
Radiologic features of pneumatosis intestinalis and portal venous
gas are typically absent. Laparotomy reveals isolated intestinal
perforation surrounded by normal bowel and usually simple
procedure such as direct suturing or resection with primary
anastomosis is the treatment of choice. More importantly,
histologic investigation commonly shows hemorrhagic necrosis
rather than coagulation necrosis [1]. Despite the differences, there
are also features common to both conditions. Prematurity is an
important and common factor in the development of NEC and
SIP. Hypoxia and shock may give rise to regional intestinal
hypoperfusion and predispose to mucosal injury resulting in
perforation in the terminal ileum, a watershed area of blood
supply and the commonest site of intestinal injury in both NEC
and SIP patients. In addition, both conditions can be associated
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1with bacterial or fungal invasion into the bloodstream or
peritoneal cavity.
Cascades of inflammatory responses as well as host defense
mechanisms against microbials and endotoxin stimulation are
likely to be triggered by NEC and SIP. Investigations on
immunoregulatory proteins in NEC and/or infection have
revealed mediators associated with pro-inflammation [4–6], anti-
inflammation [5–7], and acute proteins [8]. Interleukin (IL)-6, IL-
1b, IL-11 and tumor necrosis factor (TNF)-a have been implicated
in its pathogenesis and associated with disease severity [4,6,9,10].
To date, there have been no published data on inflammatory
mediators in SIP. In addition, profiles of immunoregulatory
proteins in NEC and SIP infants have not been systemically
evaluated nor compared. The objectives of this study were to
compare the profiles of immunoregulatory proteins in plasma of
NEC and SIP infants using cytokine array and ELISA analyses.
To investigate the association of circulating target proteins with
tissue inflammation, damage and repair, we sought to quantify
mRNA expressions of these genes in the resected bowel from NEC
and SIP patients. To further reveal the involvement of target
proteins in enterocytes, we examined their expression levels in
human fetal FHs-74 Int cells upon in vitro challenge with
lipopolysaccharide (LPS) and platelet activating factor (PAF).
Results
Clinical characteristics of infants recruited for plasma and
tissue protein analysis
The clinical characteristics of NEC and SIP infants recruited for
plasma protein analysis are presented in Table 1. Comparing
NEC with SIP infants, NEC infants, as expected, had significantly
older postnatal age at the onset of disease (P=0.002) and longer
length of bowel resection (P=0.0003). There was also a non-
significant trend of higher mortality rate in the NEC group
(P=0.085; Table 1). All control infants had benign gastrointestinal
dysmotility [11] and did not require surgery, and all of them
survived. Other comparisons between NEC or SIP infants with
their respective control groups are summarized in Table 1.
The clinical characteristics of NEC and SIP infants recruited for
tissue mRNA analysis are presented in Table 2. As expected, there
were significant differences between these subgroups of NEC and
SIP infants in postnatal age at the onset of illness (P=0.004), time
of disease onset to surgery (P=0.003) and length of bowel
resection (P=0.003). Other differences between NEC or SIP
infants and surgical control infants are summarized in Table 2.
Cytokine array profiles of NEC and SIP patients
Using a 2-fold change as the threshold (Table S1), 26 proteins
were up-regulated in NEC infants and 17 proteins in SIP infants,
compared with controls (Figure 1A). In addition, 7 and 6 proteins
were down-regulated in NEC and SIP infants, respectively
(Figure 1B). These proteins could be classified into different
functional groups of pro-inflammation (14 proteins), anti-in-
flammation (8 proteins), cell growth (6 proteins), angiogenesis (5
proteins), wound healing (3 proteins), anti-apoptosis (1 protein),
cell adhesion (1 protein), extracellular matrix reorganization (1
protein) and neuropeptide (1 protein). Importantly, some dysre-
gulated proteins were common to NEC and SIP, whereas others
were more specific to individual diseases (Figure 1). The disparity
of clinical manifestations between NEC and SIP could be further
reflected in their protein profiles (Figure 1).
Table 1. Clinical characteristics of NEC and SIP patients recruited for plasma analyses.
Preterm infants NEC NEC Control
P-value NEC
vs. NEC
Control SIP SIP Control
P-value SIP
vs. SIP
Control
P-value NEC vs.
SIP
No of infants, n 13 13 8 8
Gender, female 6 (46%) 3 (23%) 0.411 1 (12%) 2 (25%) 1.000 0.174
Gestational age, wk 28.6
(27.0–30.0)
28.6
(28.3–28.9)
0.898 25.6
(24.6–32.0)
25.6
(25.5–25.7)
0.957 0.293
Birthweight, g 980
( 810–1367)
1165
(810–1305)
0.959 793
(631–1414)
813
(726 –875)
0.916 0.311
Apgar score
1 min
6 (4–8) 7 (6–8) 0.348 8 (6–8) 7 (6–8) 0.590 0.212
Apgar score
5 min
8 (7–10) 8 (8–9) 0.895 8 (8–9) 8 (8–9) 0.868 0.766
Age commenced on
feeding, days
3 (2–5) 6 (4–10) 0.028* 8 (5–17) 11 (8–13) 0.642 0.188
Age of full feeding, days 34 (13–90) 30 (16–52) 0.738 82 (54–96) 33 (29–46) 0.121 0.195
Postnatal age at onset of
illness, days
31 (19–50) N/A N/A 9 (7–11) N/A N/A 0.002**
Duration of
hospitalization, days
138
(27–160)
88
(59–120)
0.778 121
(22–181)
116
(104–134)
0.916 0.717
Died, n 7 0 0.005** 1 0 1.000 0.085
Length of bowel
resection, cm
24.5
(22.3–31.8)
N/A N/A 3.8
(1.8–6.1)
N/A N/A 0.0003***
Results are expressed as % or median (interquartile range).
Note: N/A=not applicable.
doi:10.1371/journal.pone.0036977.t001
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suPAR by ELISA
IL-6, Angiopoietin (Ang)-2, secreted form of receptor tyrosine-
protein kinase ErbB3 (sErbB3), soluble type II interleukin-1
receptor (sIL-1RII) and soluble urokinase-type plasminogen
activator receptor (suPAR) were targeted for further validation
by ELISA (Figure 2). The results were in agreement with those
from the cytokine array, showing significant increases of IL-6,
Ang-2, sIL1-RII and suPAR in NEC infants compared with NEC-
CTL infants (P,0.01; Figure 2A, B, D, E). In contrast, levels of
these proteins in SIP infants did not significantly differ from SIP-
CTL infants. There were also no significant differences between
the SIP and NEC group, except that SIP infants had significantly
higher plasma level of sErbB3 compared with NEC infants
(P,0.05; Figure 2C).
In the NEC group, there was a significant positive correlation
between Ang-2 and sIL1-RII (r=0.643, P=0.018). Significant
inversed correlations were shown between IL-6 and sErbB3
(r=20.56, P=0.046), as well as between suPAR and platelet
counts (r=20.791; P=0.001). A non-significant trend between
Ang-2 and suPAR was also observed (r=0.511, P=0.074;
Figure S1).
mRNA expression levels of IL-6, Ang-2, ErbB3, IL1-RII, and
uPAR in resected intestinal tissues
To investigate the regulation of target proteins at the tissue level,
we quantified mRNA expressions of these genes in resected tissues
from NEC (n=7) and SIP (n=6) infants (Figure 3). The qPCR
results revealed that IL-6, IL1-RII and uPAR expressions were
significantly higher (P,0.01) in NEC tissues compared with
control tissues (n=6; Figure 3A, D and E). In contrast, mRNA
expression levels of these target genes were similar between SIP
and control tissues. There were also no significant differences in
mRNA expression levels of target genes between NEC and SIP
infants.
mRNA expression levels of IL-6, Ang-2, IL1-RII, and uPAR
in FHs-74 Int cell line upon stimulation with LPS and/or
PAF
Combined treatments with LPS and PAF significantly increased
expression levels of Ang-2, IL1-RII and uPAR in FHs-74 Int cells
upon culture at a reduced serum concentration (P,0.05;
Figure 4B, C and D). Treatment with single stimulant, either
LPS or PAF, did not significantly alter the expression levels,
though a non-significant trend of increase was observed in the PAF
cultures.
Discussion
This study reported the first comparative profiles of immuno-
regulatory proteins in plasma of NEC and SIP infants and showed
that dysregulated proteins belonged to functionally diversified
categories. Overall, the number of immunoregulatory proteins and
their magnitude of changes appeared more severely altered in
NEC infants, especially within categories of pro- and anti-
inflammation, compared with SIP infants. In addition, specific
anti-apoptosis, cell adhesion and extracellular matrix proteins
were only down-regulated in NEC patients, possibly revealing the
different nature of bowel injury and/or severity of inflammation
compared with SIP. Further validation of selected targets
confirmed up-regulation of IL-6, Ang-2, sIL1-RII and suPAR in
NEC infants compared with gestational age-matched controls, but
the circulating level of sErbB3 was significantly decreased
compared with SIP infants. mRNA expressions of IL-6, IL1-RII
and uPAR were up-regulated in resected bowel tissues from NEC
infants and in accordance with changes in plasma proteins. This
indicated that immunomodulation had occurred at the tissue and
cellular levels of the affected bowel, which could have contributed
Table 2. Clinical characteristics of NEC, SIP and surgical control patients recruited for mRNA analysis.
Preterm infants NEC SIP Surgical Control
P-value NEC vs.
Surgical Control
P-value SIP vs.
Surgical Control
P-value NEC vs.
SIP
No of infants, n 7 6 6
Gender, female 3 (43%) 1 (17%) 2 (33%) 1.000 1.000 0.559
Gestational age, wk 28 (26.4–29.3) 25.3 (24.7–30.5) 35.9 (34.0–37.7) 0.032* 0.030* 0.391
Birthweight, g 870 (770–984) 793 (671–1675) 2730 (2073 –2889) 0.015* 0.109 0.668
Apgar score 1 min 6 (3–8) 8 (6–9) 9 (8–9) 0.066 0.276 0.277
Apgar score 5 min 7 (5–9) 8 (8–10) 10 (9–10) 0.060 0.138 0.337
Age commenced on
feeding, days
3 (3–14) 8 (8–9) 12 (12–15) 0.514 0.344 0.568
Age of full feeding, days 90 (75–110) 82 (58–95) 92 (29–97) 0.655 0.806 0.724
Postnatal age at onset of
illness, days
50 (32–56) 10 (9–12) 4 (1–58) 0.317 0.469 0.004**
Duration of
hospitalization, days
153 (104–167) 121 (39–171) 37 (25–84) 0.153 0.575 0.668
Time of disease onset to
surgery, h
48 (44–58) 5 (4–8) 24 (24–48) 0.207 0.006** 0.003**
Died, n 3 1 0 0.192 1.000 0.559
Length of bowel
resection, cm
25.0 (19.0–30.5) 2.6 (1.4–5.7) 12.3 (6.5–17.6) 0.046* 0.092 0.003**
Results are expressed as % or median (interquartile range).
Note: All surgical specimens were of ileal origin, except 1 SIP specimen was from the descending colon.
doi:10.1371/journal.pone.0036977.t002
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human fetal enterocytic cell line FHs-74 Int, Ang-2, IL1-RII and
uPAR expressions were significantly induced by the combined
treatment with LPS and PAF, again suggested that these genes
could act synergistically and play a pivotal role in disease
development and progression of NEC.
Using cytokine array as a hypothesis-free approach, we
provided specific profiles of plasma immunoregulatory proteins
in NEC and SIP infants. Our findings are in line with other studies
on cytokines, showing regulation of pro- and anti-inflammatory,
and repair-associated proteins in NEC infants, including IL-6, IL-
8, IL-10, TNF, ENA-78, matrix metalloprotease-9, GRO, MCP-1
and IGF-1 [4–7,12–15]. We have also discovered novel immuno-
regulatory proteins such as Ang-2, ErbB3 and uPAR, which have
not been previously described in NEC or SIP. Importantly, there
have not been any comprehensive data on immunoregulatory
proteins reported in SIP. Our plasmatic protein profile thus
represents the basic information platform for further mechanistic
investigation of this disease.
Despite sharing many common dysregulated immunomodula-
tory proteins in the two conditions, some appeared to be more
specific to either NEC or SIP, thus reflecting differences regarding
the etiology, pathophysiology and severity of inflammation of the
two conditions. We validated IL-6, Ang-2, IL1-RII and uPAR in
Figure 1. Differentially expressed immunoregulatory proteins in NEC and SIP infants. The plasma profiles of 174 immunoregulatory
proteins in infants with NEC (n=5) and SIP (n=4) were compared with those in gestational age-matched control infants (n=5; CTL), using the human
Cytokine Antibody Array assay. Using a 2-fold change as the cut- off criterion, differentially up-regulated [Figure 1A] and down-regulated [Figure 1B]
proteins in NEC and SIP relative to CTL infants were listed under functional categories.
doi:10.1371/journal.pone.0036977.g001
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enterocyte model, suggesting that the systemic dysregulation of
these proteins not only occurred at the plasma level, but also at the
cellular level of inflamed bowel tissues and enterocytes. The
evidence suggested up-regulation of IL-6, Ang-2, sIL1-RII and
suPAR in NEC infants, whereas sErbB3 was significantly higher in
the plasma of SIP compared with NEC infants. Despite changes of
immunoregulatory proteins were observed in the plasma of SIP
patients, the targeted gene levels in the bowel specimens were not
different from tissues of surgical control subjects. This might reflect
minimal intestinal inflammation due to the localized nature of
bowel perforation. The exaggerated up-regulation of immuno-
modulatory proteins in NEC infants represented imbalance of the
inflammatory cascade, which could lead to necrosis, apoptosis and
severe tissue damage. This could account for the high morbidity
and mortality rate in NEC compared with SIP infants. Of clinical
interest, further investigation on validating these dysregulated
proteins in a cohort study, either individually or in combination as
diagnostic biomarkers, might reveal their usefulness for early
differentiation of NEC from SIP patients.
Increased production of the pleiotropic cytokine IL-6 is the
hallmark of inflammatory diseases and sepsis. The magnitude of
increase reflected the severity of inflammation and has been
associated with adverse outcomes such as disseminated intravas-
Figure 2. Comparison of plasma levels of target proteins in NEC, SIP and respective control infants by ELISA. Levels of IL-6, Ang-2,
sErbB3, sIL1-RII, and suPAR in NEC (n=13) and SIP (n=8) infants were quantified by ELISA and compared with those in respective gestational age-
matched control (CTL) infants (NEC CTL, n=13; SIP CTL, n=8). Levels of IL-6, Ang-2, sIL1-RII and suPAR were significantly higher in NEC infants
compared with NEC-CTL (P,0.01) (Figure 2A, B, D, E) and SIP infants had significantly higher level of sErbB3 compared with NEC infants (P,0.05)
(Figure 2C). Results are presented as median, interquartile range and range.
doi:10.1371/journal.pone.0036977.g002
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[4,9,14,16,17]. Thus, the marked up-regulation of IL-6 and other
pro-inflammatory mediators (Figure 1) could provide an explana-
tion for the substantially higher mortality in NEC compared with
SIP infants. It has also been suggested that the imbalance of pro-
inflammatory to anti-inflammatory cytokines such as a persistently
high IL6/IL-10 ratio could predict increased mortality of critically
ill adult and neonatal patients [16,18]. We analyzed this ratio in
both NEC and SIP infants and demonstrated that a non-
significant trend (P=0.158; Figure S2) existed between those
who survived (n=13) and died (n=8). It is envisaged that a larger
sample size with longitudinal monitoring would be required to
fully address the prognostic value of IL-6/IL-10 ratio in surgical
infants. IL-6 has been reported to regulate the severity of LPS-
driven pro-inflammatory responses via STAT3 and cross-talk
between JAK/STAT and toll-like receptor pathways [19]. PAF
induced expression of IL-6 was also observed in different cellular
systems including adult leukocytes [20,21], endothelial cells [22]
and gut mucosa in a rat model of intestinal damage [23].
Upregulation of IL-6 mRNA was detected in resected tissues from
NEC patients, but not in FHs-74 Int enterocytes upon in vitro
stimulation by LPS and PAF. This observation suggests possible
presence of multiple cellular sources of IL-6 production such as
endothelial cells and infiltrated leukocytes in inflammed bowel
tissues.
Ang-2, an endothelium-specific growth factor, is known to be
upregulated in sepsis and inflammatory bowel diseases (IBD) such
as Crohn’s disease and ulcerative colitis in adults [24,25]. Ang-2 is
involved in angiogenesis and plays a key role in the pathogenesis of
IBD [25]. It is positively associated with pro-inflammatory
Figure 3. mRNA expression levels of target genes in resected intestinal tissues of NEC and SIP infants. Expression levels of IL-6, Ang-2,
ErbB3, IL1-RII, and uPAR in resected intestinal tissues from NEC (n=7) and SIP (n=6) infants were quantified by qPCR and compared with surgical
control tissues (n=6). Results showed that IL-6, IL1-RII and uPAR were significantly higher (P,0.01) in NEC tissues, compared with surgical control
tissues (Figure 3A, D and E). Results are presented as median, interquartile range and range of expression levels relative to b-actin.
doi:10.1371/journal.pone.0036977.g003
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disrupts vascular quiescence by antagonizing the protective Tie-2
signaling [27], resulting in vascular leakage [24]. Ang-2 also
activates neutrophils and enhances PAF synthesis in human
endothelial cells [28]. We speculate that Ang-2 may further
aggravate the inflammatory cascade and contribute to the
pathophysiology of NEC by destabilizing vascular endothelium
and increasing vascular leakage.
ErbB3 is expressed in epithelial cells throughout the gastroin-
testinal tract [29] and sErbB3 is the secreted form of ErbB3
receptor. ErbB3 binds to the ligand, heregulin and blocks it from
binding to the cell surface receptor for induction of cell pro-
liferation and differentiation [30]. To date, most studies have
associated ErbB3 and sErbB3 with breast and prostate cancers
[31,32] and there has been no report coupling these mediators
with systemic inflammatory or gastrointestinal diseases in human.
In SIP infants, sErbB3 might inhibit ErbB3 receptor activation on
intestinal epithelial cells, thereby limiting cell proliferation and
differentiation. This could potentially increase the risk of intestinal
perforation.
sIL-1RII is an IL-1b scavenger which negatively regulates the
pro-inflammatory signals of IL-1. sIL-1RII is known to be elevated
in plasma of septic patients, especially the critically-ill [33,34].
LPS, TNF-a and other chemoattractants could mediate the release
of sIL-1RII [35,36]. It has been suggested that local shedding of
sIL-1RII may decrease colonic inflammation in Crohn’s disease
[37]. Similarly, it would be plausible that sIL-1RII was released
from the site of NEC as a mechanism to regulate and dampen
acute reactions of the inflammatory cascade.
Leukocyte is the major site of suPAR production and it
functions as a scavenger for inhibiting uPAR signaling, co-
ordinating extracellular matrix proteolysis, promoting cell migra-
tion, adhesion and survival [38,39]. An increase in circulating
suPAR level has been implicated in inflammation and sepsis [40],
and it has been suggested as a prognostic biomarker of disease
severity and fatality in patients with bacteremia [41,42]. These
observations are in accordance with our results that uPAR was
markedly increased in the plasma of NEC but not in SIP infants.
The significantly higher expression of uPAR in resected intestinal
tissues of NEC compared with those of SIP would be consistent
with its pivotal role in leukocyte recruitment and adhesion, as well
as matrix remodeling.
PAF and LPS are frequently used as stimulants in experimental
NEC models as they are key mediators in the pathogenesis of NEC
in premature infants [43,44]. In human enterocytes, LPS is
recognized by toll-like receptor (TLR)-4 and involves in activating
transcription of pro-inflammatory cytokines IL-8 and TNF [45].
In the current mRNA analysis, we observed that three target genes
were significantly upregulated upon combined, but not with
individual LPS or PAF treatment, indicating that these two factors
could act synergistically in regulating tissue and circulating
immunoregulatory proteins. Our findings pointed to multiple
levels of gene dysregulations involving proinflammation, anti-
inflammation, cell repair and angiogenesis, which might contrib-
ute to the pathophysiology of NEC. We propose that LPS and
PAF could activate the inflammatory cascade, leading to
exaggerated production of pro-inflammatory proteins such as
TNF-a and MMP, which in turn stimulate expressions of other
Figure 4. mRNA expression levels of target genes in FHs-74 Int cell line in response to LPS and PAF. FHs-74 Int cells were cultured in the
presence of LPS (100 ng/mL) or PAF (25 mM) for 6 h individually or in combination. qPCR analysis of target mRNA expressions showed that combined
treatment with LPS and PAF significantly increased levels of Ang-2, IL1-RII and uPAR (n=4; P,0.05), whereas single stimulant, LPS or PAF, did not
alter the expression levels. Results are presented as mean and SEM of expression levels relative to b-actin.
doi:10.1371/journal.pone.0036977.g004
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overall mechanism, however, could be highly complex as these
proteins are inter-regulatory and may exert positive and negative
feedbacks at different levels of the inflammatory cascade.
However, it is important to acknowledge that the FHs-74 Int cell
model represents only a single cell type amongst multiple cell
moieties in the in vivo intestinal system, which also harbors the
microbiome and infiltrating leukocytes capable of interfering with
regulatory pathways.
In summary, our study provided the plasmatic signatures of
immunoregulatory proteins in NEC and SIP infants, and
demonstrated that multiple mechanistic pathways have been
involved. The exaggerated response profile in NEC infants
represented an intense activation of the inflammatory cascade
and could account for the cytokine imbalance resulting in the high
mortality rate observed in NEC compared with SIP infants.
Further quantitative analysis of IL-6, Ang-2, sIL-1RII and suPAR
revealed regulations at both systemic and cellular levels, possibly
mediated by bacterial endotoxin LPS, endogenous PAF and early
pro-inflammatory cytokines. Dysregulated angiogenesis and cell
repair pathways could eventually contribute to tissue damage and
cell death. Our results, thus, provide insights for future investiga-
tions. Longitudinal monitoring of novel plasma immunoregulatory
proteins and their kinetics could reveal their associations with
disease progression. This would allow evaluation of their suitability
as diagnostic biomarkers for early differentiation of NEC and SIP,
as well as for explaining and predicting the severity and prognosis
of these conditions.
Materials and Methods
Experimental design and patient population
A total of 13 NEC and 8 SIP infants requiring surgical
intervention were recruited into the study within a 50-month
period starting in January 2007. All cases of NEC with histologic
confirmation were classified by the modified Bell’s criteria to have
Stage 3 disease. Plasma and tissue samples from these infants were
investigated and compared with an equivalent number of control
infants.
In the first phase of the study (i.e., within the first 18 months of
patient recruitment), we screened and compared the plasma
profile of 174 immunoregulatory proteins in infants with NEC
(n=5), SIP (n=4) and gestational age-matched controls (CTL;
n=5) using the human Cytokine Antibody Array. CTL infants
had clinical features suggestive of gastrointestinal dysfunction but
were subsequently diagnosed to have benign gastrointestinal
dysmotility of prematurity [11] without NEC, SIP or septicemia.
Based on Cytokine Array data, potential target proteins were
selected on criteria of their relative expression levels, novelty and
reversed trend of changes in NEC versus SIP. Subsequently, levels
of these target proteins were validated by ELISA in all 13 NEC
and 8 SIP infants by comparing with their respective CTL infants
(NEC-CTL, n=13; SIP-CTL, n=8).
In the second phase of the study, we investigated the regulation
of target proteins at the tissue level in the same cohort of NEC and
SIP infants. Tissue specimens were unavailable for mRNA analysis
in: (i) fatal ‘‘open and close’’ cases of NEC (n=3); (ii) full thickness
necrotic specimen (n=1); (iii) cases with no tissue collection (n=2);
and (iv) SIP infants with primary suturing of perforation (n=2).
mRNA expressions in affected intestinal tissues from NEC (n=7),
SIP (n=6) and an independent group of surgical control infants
(n=6) were compared by quantitative polymerase chain reaction
(qPCR). The surgical control infants were not affected by NEC,
SIP nor septicemia, but underwent abdominal surgery due to
congenital small bowel atresia (n=4) and anatomical obstruction
(n=2). These infants were of older gestational age (medium
35.9 weeks, range 34.0–37.7 weeks). All tissue specimens from
NEC, SIP and surgical control infants were of ileal origin, except
that one specimen of the SIP group was obtained from the
descending colon.
In the third phase, the response of selected genes to bacterial
endotoxin LPS and stimulant PAF at the mRNA expression levels
was determined in the model of human normal fetal enterocyte
cell line FHs-74 (n=4).
Blood samples (0.5 mL) were collected 1–6 h immediately
before surgery. We standardized blood sampling to be performed
immediately after the decision of surgery was confirmed, as it
represented the time when infants were most sick and surgery was
imminent and unavoidable. All blood samplings coincided with
collections for clinical testing so as to minimize disturbance to the
infants. Clinical characteristics of all NEC and SIP infants, as well
as those provided surgical specimens are described in Table 1 and
2, respectively. One of 8 SIP infants received dexamethasone on
the day of surgery, whereas no NEC patients were treated with
systemic corticosteroids or non-steroid anti-inflammatory drugs.
Protein analysis by cytokine antibody array and enzyme-
lined immunosorbent assays (ELISA)
The plasma fraction was separated by centrifugation (1900 g for
10 min) at 4uC and stored in 50 mL aliquots at 280uC until
analysis. Relative concentrations of immunoregulatory proteins
were measured by the Human Cytokine Antibody Array C Series
2000 kit according to the manufacturer’s protocol (RayBiotech,
Norcross, GA, USA). The 3 membrane arrays 6, 7 and 8
(catalogue number: AAH-CYT-6, AAH-CYT-7, AAH-CYT-8
respectively) covered 174 immunoregulatory proteins. The signal
intensity was detected by enhanced chemiluminescence (ECL),
(Amersham Biosciences, Little Chalfont, UK) and exposure to X-
ray film (Kodak, Rochester, NJ). Quantification of spots was then
performed using the GS-700 Imaging Densitometer and the
QuantityOne software (BioRad, Richmond, CA, USA). The mean
normalized densitometric value from duplicates of each immuno-
regulatory molecule was obtained using the RayBioH Analysis
Tool with background subtraction. Results are expressed as
normalized intensities.
Selected protein targets, IL-6, Ang-2, sErbB3, sIL-1RII and
suPAR, were quantified in plasma samples of all recruited NEC
(n=13) and SIP (n=8) infants, and respective CTL (NEC-CTL,
n=13; SIP-CTL, n=8) by ELISA kits (R&D Systems, Minnea-
polis, MN, USA and Raybiotech) according to the manufacturer’s
instruction.
Measurement of mRNA expression levels in intestinal
tissue by qPCR
Immediately after resection, tissue specimens were rinsed with
cold phosphate-buffered saline, snap-frozen in liquid nitrogen and
then stored at 280uC until tissue homogenization. Total RNA was
extracted using TRIZOL reagent (LifeTechnologies, Gaithers-
burg, MD) and RNeasy mini kit (QIAGEN, GmbH, Hilden,
Germany). Gene expression levels of IL-6, Ang-2, ErbB3, IL-1RII
and uPAR were quantified and compared with those in surgical
control tissues by qPCR using pre-designed or custom-designed
TaqMan assays (Applied Biosystems, Foster City, CA). Amplifi-
cation was performed for 40 cycles with denaturation at 95uC for
15 sec, annealing at 60uC for 1 min. The emission intensity was
detected by the ABI 7300 Real-Time PCR System (Applied
Biosystems). The average threshold cycles (Ct) were used to
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Biosystems).
In vitro stimulation of human cell line FHs-74 Int by LPS
and PAF
The normal fetal intestinal FHs-74 Int cell line (American Type
Culture Collection, ATCC, Rockville, MD, USA) was maintained
in Hybri-Care Medium 46-X (ATCC) supplemented with 30 ng/
mL human epidermal growth factor (R&D Systems) and heat-
inactivated fetal bovine serum (FBS, 10%), penicillin G (100 IU/
mL) and streptomycin (100 mg/mL) (Invitrogen, Carlsbad,
California) at 37uC in a humidified incubator containing 5%
CO2. FHs-74 Int cells (1.5610
5/mL) were cultured for 24 h with
reduced FBS at 5% and then treated with LPS (100 ng/mL;
Sigma, Saint Louis, MO, USA) or PAF (25 mM; Biomol Research
Laboratories, Plymouth Meeting, PA, USA) for 6 h individually
and also with these two stimulants in combination. mRNA
expression levels of target genes IL-6, Ang-2, IL-1RII and uPAR
were determined by qPCR.
Statistical analysis
This was performed using the GraphPad PRISM program
version 5.02 for Windows (Graphpad Software, San Diego, CA,
USA) and SPSS (Version 17, Chicago, IL). Clinical data of NEC,
SIP and respective control groups were evaluated by the Fisher’s
exact test and Mann Whitney U test as appropriate. Expression
levels of target proteins between NEC or SIP and their respective
control groups, as well as between NEC and SIP in plasma and
resected intestinal tissues were compared by the Kruskal-Wallis
test. Data on mRNA expression of target genes in the intestinal cell
line upon treatments with LPS and PAF were analysed using the
Friedman test, followed by the post-hoc Dunn’s comparison.
Linear correlations between plasma proteins, CRP and platelet
counts were calculated using the Spearman’s correlation test.
Results are expressed as median and interquartile range, or as
mean and standard error of the mean (SEM). A P value of #0.05
is considered statistically significant.
Ethics statement
All blood and tissue samples were collected with written
parental consent and in accordance with procedures approved
by the Ethics Committee for Clinical Research, The Chinese
University of Hong Kong.
Supporting Information
Figure S1 Correlation between target proteins in NEC
infants. Plasma levels of IL-6, Ang-2, sIL1-RII, suPAR and
sErbB3 in NEC (n=13) infants were analyzed by the Spearman’s
correlation test, which showed a significant positive correlation
between [A] Ang-2 and sIL1-RII, a significant inverse correlation
between [B] IL-6 and sErbB3, as well as [C] suPAR and platelet
count. A non-significant trend existed between [D] Ang-2 and
uPAR.
(TIF)
Figure S2 IL-6/IL-10 ratio in NEC and SIP patient
subgroups. The ratio of IL-6/IL-10 protein levels was analyzed
on all plasma samples from NEC and SIP patients (n=21). There
was a non-significant trend (P=0.158) of higher IL-6/IL-10 ratio
on combined NEC and SIP patients who died (n=8; median IL-
6/IL-10 ratio: 3.52; interquartile range: 2.83–7.20), compared
with those who survived (n=13; median IL-6/IL-10 ratio: 1.63;
interquartile range: 0.57–5.29).
(TIF)
Table S1 Comparison of relative protein levels in
plasma of NEC, SIP and control infants.
(DOC)
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